Sep 2026· European Journal Pharmaceutical and Medical Research
Abstract
Driven by artificial intelligence, or AI, today's medicinal science has the potential of rapidly transforming a doctor's knowledge of patient reactions to a variety of medications. In clinical practice, one has seen that sometimes a given medication is effective and sometimes ineffective in a patient. This difference could be caused by genetics, lifestyle, disease conditions, environmental exposure or none of the above. With the advent of AI, drug response prediction and optimization are now better supported with many various approaches. Random Forest (RF) and Support Vector Machine (SVM) are some of the common machine learning algorithms employed to predict the activity of a particular drug, identify the biomarkers and classify patients as responders and non-responders. These techniques aid doctors with the informed decisions, particularly regarding chemotherapy. Gradient Boosting models also predict clinical risks and bad drug reactions with lot of precision, such as XGBoost, and LightGBM. The use of complex biological patterns by deep learning models is enhancing the field of pharmacology research further. The use of Artificial neural Networks (ANNs) to explore drug interactions with the target and to simulate Pharmacokinetics – the mechanisms of body uptake, distribution and disposition of drugs. CNNs also are extremely effective when performing image analysis tasks, such as detecting tumors or modeling and assessing the effectiveness of cancer medications with medical images. The Recurrent Neural Networks (RNNs) are designed to see data changing over time and so help doctors stay abreast of patients' progress and predict their long-term outcomes. More sophisticated AI techniques are making a large impact too. Graphical models are used to describe complex molecular and drug–drug network data and graphical networks are used in Graph Neural Networks (GNNs) to understand the relationships between different molecules and drugs. This is really important to identify safe and effective combined therapies. Drug Safety Monitoring and Evidence-Based Decision Making can be enhanced through the use of Natural Language Processing (NLP), as this technology can extract valuable information from clinical notes, research articles, and electronic health records. Using Reinforcement Learning (RL), flexible treatment plans can be developed by optimising the dose of drug administration in real-time. Pro-bayarian networks: Bayes models when a doctor doesn’t know what to do. Combination of clinical with multi-omics data (including genomic, transcriptomic, and proteomic data) is one of the most powerful of AI. Such a combination helps understand disease mechanisms and patient variability better, resulting in improved patient stratification, personalized dosages and therapeutic outcomes.
This paper investigates developing real-world perception for active agents, proposes Gibson Environment for this purpose, and showcases a set of perceptual tasks learned therein.
F. Xia, Amir Zamir, Zhi-Yang He et al.· 2018 IEEE/CVF Conference on...· 1,069 citations· ⚡112
The results indicate that software engineering work practices are chosen opportunistically, adapted and configured to provide value under the constrains imposed by the startup context.
Nicolò Paternoster, Carmine Giardino, M. Unterkalmsteiner et al.· Information and Software Tec...· 394 citations· ⚡54
GAOKAO-Bench is introduced, an intuitive benchmark that employs questions from the Chinese GAOKAO examination as test samples, including both subjective and objective questions that contribute a robust evaluation benchmark for future large language models and offers valuable insights into the advantages and limitations...
Xiaotian Zhang, Chun-yan Li, Yi Zong et al.· arXiv.org· 216 citations· ⚡17
An algorithm is proposed which leverages disentangled semantic factors to generate adversarial perturbation by altering controlled semantic attributes to fool the learner towards various "adversarial" targets.
Haonan Qiu, Chaowei Xiao, Lei Yang et al.· arXiv.org· 208 citations· ⚡17
This work proposes a HALO that directly maximizes the utility of generations instead of maximizing the log-likelihood of preferences, and suggests that the best loss depends on the inductive biases most appropriate for a given setting, an oft-overlooked consideration.
The results are packaged in the Greenfield Startup Model (GSM), which explains the priority of startups to release the product as quickly as possible, and the need to shorten time-to-market, by speeding up the development through low-precision engineering activities.
Carmine Giardino, Nicolò Paternoster, M. Unterkalmsteiner et al.· IEEE Transactions on Softwar...· 178 citations· ⚡14
Related blog posts
MIT News · Artificial Intelligence· news.mit.eduOct 13, 2026
Machine-learning networks can learn without detailed instructions from a designer. Those that do may offer insight into how the brain reorganizes itself during learning.